234 related articles for article (PubMed ID: 37533600)
21. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre.
Li G; Zhao Y; Li K; Yang S; Xiang C; Song J; Yang Y; Li G; Dong J
J Hepatocell Carcinoma; 2023; 10():2037-2048. PubMed ID: 37965075
[TBL] [Abstract][Full Text] [Related]
23. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
Zou X; Xu Q; You R; Yin G
Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study.
Lu H; Zheng C; Liang B; Xia X; Fan H
Front Oncol; 2024; 14():1280837. PubMed ID: 38298738
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization.
Lin LW; Ke K; Yan LY; Chen R; Huang JY
Front Oncol; 2023; 13():1178428. PubMed ID: 37207144
[TBL] [Abstract][Full Text] [Related]
26. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
An C; Fu Y; Li W; Zuo M; Wu P
Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
[TBL] [Abstract][Full Text] [Related]
27. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis.
Ahn YE; Suh SJ; Yim HJ; Seo YS; Yoon EL; Kim TH; Lee YS; Yim SY; Kim HR; Kang SH; Jung YK; Kim JH; Yeon JE; Um SH; Byun KS
Gut Liver; 2021 Mar; 15(2):284-294. PubMed ID: 32307975
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy analysis of hepatic arterial infusion chemotherapy combined with targeted and immune therapy followed by
Wang M; Zhou ZG; Lu TY; Du KP; Li S; Gao F; Li YD; Gao MY
Zhonghua Yi Xue Za Zhi; 2024 Jan; 104(4):290-296. PubMed ID: 38246774
[No Abstract] [Full Text] [Related]
30. Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
Xiao Y; Zhu G; Xie J; Luo L; Deng W; Lin L; Tao J; Hu Z; Shan R
J Hepatocell Carcinoma; 2023; 10():2049-2058. PubMed ID: 37965074
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma.
Xu Y; Fu S; Mao Y; Huang S; Li D; Wu J
Front Med (Lausanne); 2022; 9():919069. PubMed ID: 36117969
[TBL] [Abstract][Full Text] [Related]
32. Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor-1 in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study.
Chang X; Wu H; Ning S; Li X; Xie Y; Shao W; Yu J
J Hepatocell Carcinoma; 2023; 10():1497-1509. PubMed ID: 37701565
[TBL] [Abstract][Full Text] [Related]
33. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study.
Ji X; Xu Z; Sun J; Li W; Duan X; Wang Q
Radiat Oncol; 2023 Jun; 18(1):101. PubMed ID: 37308914
[TBL] [Abstract][Full Text] [Related]
34. TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study.
Yang B; Jie L; Yang T; Chen M; Gao Y; Zhang T; Zhang Y; Wu H; Liao Z
Front Oncol; 2021; 11():821599. PubMed ID: 35004336
[TBL] [Abstract][Full Text] [Related]
35. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
36. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
[TBL] [Abstract][Full Text] [Related]
37. Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Li SQ; Wu JY; Wu JY; Xie H; Li JH; Zeng ZX; Fu YK; Liu DY; Li H; Chen WZ; Huang JY; Yan ML
J Hepatocell Carcinoma; 2023; 10():1799-1811. PubMed ID: 37850080
[TBL] [Abstract][Full Text] [Related]
38. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Li Q; Cao M; Yuan G; Cheng X; Zang M; Chen M; Hu X; Huang J; Li R; Guo Y; Ruan J; Chen J
Front Oncol; 2022; 12():809709. PubMed ID: 35280760
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the Benefits of TACE Combined with Lenvatinib Plus PD-1 Inhibitor for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
Zou X; Xu Q; You R; Yin G
Adv Ther; 2023 Apr; 40(4):1686-1704. PubMed ID: 36805422
[TBL] [Abstract][Full Text] [Related]
40. Combined iodine-125 seed strand, portal vein stent, transarterial chemoembolization, lenvatinib and anti-PD-1 antibodies therapy for hepatocellular carcinoma and Vp4 portal vein tumor thrombus: A propensity-score analysis.
Zhang ZH; Hou SN; Yu JZ; Zhang W; Ma JQ; Yang MJ; Liu QX; Liu LX; Luo JJ; Qu XD; Yan ZP
Front Oncol; 2022; 12():1086095. PubMed ID: 36741718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]